Dianthus Therapeutics, Inc. /DE/ Increase (Decrease) in Deferred Revenue
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Increase (Decrease) in Deferred Revenue of $510.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$339.00K.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was $849.00K.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$64.00K, a 102.68% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $4.76M.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for fiscal 2025 was $4.57M, a 91.50% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for fiscal 2024 was $2.39M.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in deferred revenue for fiscal 2022 was $891.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 6 month as first filed | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $510.00K 10-Q · filed 2026-08-04 | $446.00K derived: sum of 3 quarters · filed 2026-08-04 | $5.20M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $849.00K 10-Q · filed 2026-05-05 | $785.00K derived: sum of 2 quarters · filed 2026-05-05 | $5.54M derived: sum of 3 quarters · filed 2026-05-05 | $5.48M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.69M derived: sum of 2 quarters · filed 2026-03-09 | $4.63M derived: sum of 3 quarters · filed 2026-08-04 | $4.57M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $4.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.69M derived: sum of 2 quarters · filed 2026-08-04 | $4.63M 10-Q · filed 2025-11-05 | $7.02M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$123.00K 10-Q · filed 2026-08-04 | $2.26M derived: sum of 3 quarters · filed 2026-08-04 | $2.26M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$57.00K 10-Q · filed 2026-05-05 | $2.33M derived: sum of 2 quarters · filed 2026-05-05 | $2.33M derived: sum of 3 quarters · filed 2026-05-05 | $2.33M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.39M derived: sum of 2 quarters · filed 2026-03-09 | $2.39M derived: sum of 3 quarters · filed 2026-03-09 | $2.39M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | -$96.00K 10-Q · filed 2024-11-07 | $46.00K derived: sum of 4 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | -$54.00K 10-Q · filed 2024-08-08 | $46.00K derived: sum of 3 quarters · filed 2025-08-07 | $28.00K derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | -$17.00K 10-Q · filed 2024-05-09 | $46.00K derived: sum of 2 quarters · filed 2025-05-12 | $28.00K derived: sum of 3 quarters · filed 2025-05-12 | $9.00K derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $28.00K derived: sum of 2 quarters · filed 2025-03-11 | $9.00K derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 | -$55.00K 10-K · filed 2024-03-21 | |||
| 2023-09-30 | -$18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$37.00K derived: sum of 2 quarters · filed 2024-11-07 | -$46.00K 10-Q · filed 2024-11-07 | -$69.00K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$28.00K 10-Q · filed 2024-08-08 | -$51.00K derived: sum of 3 quarters · filed 2024-08-08 | |||||
| 2023-03-31 | -$9.00K 10-Q · filed 2024-05-09 | -$32.00K derived: sum of 2 quarters · filed 2024-05-09 | ||||||
| 2022-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $891.00K 10-K · filed 2024-03-21 | ||||||
| 2022-09-30 | $914.00K 10-Q · filed 2023-11-09 | |||||||
| 2021-12-31 | $0.00 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |